<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01694446</url>
  </required_header>
  <id_info>
    <org_study_id>Glucose 090428B</org_study_id>
    <nct_id>NCT01694446</nct_id>
  </id_info>
  <brief_title>Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose</brief_title>
  <acronym>glucose</acronym>
  <official_title>Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increased postprandial plasma triglycerides are associated with increased cardiovascular&#xD;
      risk. Chronic consumption of carbohydrates is associated with increased levels of&#xD;
      triglycerides. Very few studies have assessed the effect of acute consumption of&#xD;
      carbohydrates on plasma triglycerides and lipoprotein production and clearance. The present&#xD;
      study aims to assess the effects of acute administration of glucose and fructose on hepatic&#xD;
      and intestinal lipoprotein production.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each subject will be studied twice 4-6 weeks apart in random order in this single blinded&#xD;
      study. A nasoduodenal tube will be sited under fluoroscopic guidance the day prior to the&#xD;
      study.In study A they will receive intraduodenal intralipid (20% at 60 ml/hour) alongside 60&#xD;
      ml/hour of 20% dextrose or fructose for 15 hours starting at 4am. In study B they will&#xD;
      receive 60 ml/hour of intraduodenal intralipid with 60ml/hour of normal saline for 15 hours&#xD;
      from 4am. A pancreatic clamp (octreotide with replacement glucose, insulin, glucagon and&#xD;
      growth hormone) will be started at 7am. From 9am an iv bolus of deuterated-glycerol&#xD;
      (d5-glycerol) along with a regular infusion of deuterated leucine (L-[5,5,5-2H3]. Regular&#xD;
      blood samples will be drawn to assess lipoprotein kinetics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of intestinal and hepatic lipoprotein production</measure>
    <time_frame>10 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Intraduodenal glucose or fructose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intraduodenal glucose or fructose</intervention_name>
    <arm_group_label>Intraduodenal glucose or fructose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women, aged 18 to 60 years&#xD;
&#xD;
          2. Body mass index 20 kg/m2 to 27 kg/m2&#xD;
&#xD;
          3. Hemoglobin above 130g/L.&#xD;
&#xD;
          4. Normal glucose tolerance in response to a 75g, 2-hr OGTT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a history of hepatitis/hepatic disease that has been active within the&#xD;
             previous two years.&#xD;
&#xD;
          2. Any significant active (over the past 12 months) disease of the gastrointestinal,&#xD;
             pulmonary, neurological, renal (Cr &gt; 1.5 mg/dL), genitourinary, hematological systems,&#xD;
             or has severe uncontrolled treated or untreated hypertension (sitting diastolic BP &gt;&#xD;
             100 or systolic &gt; 180) or proliferative retinopathy&#xD;
&#xD;
          3. History of diabetes or OGTT indicative of diabetes or impaired glucose tolerance.&#xD;
&#xD;
          4. Any history of a MI or clinically significant, active, cardiovascular history&#xD;
             including a history of arrhythmia's or conduction delays on ECG, unstable angina, or&#xD;
             decompensated heart failure.&#xD;
&#xD;
          5. Any laboratory values: AST &gt; 2x ULN; ALT &gt; 2x ULN TSH &gt; 6 mU/l&#xD;
&#xD;
          6. Current addiction to alcohol or substances of abuse as determined by the investigator.&#xD;
&#xD;
          7. Mental incapacity, unwillingness or language barrier precluding adequate understanding&#xD;
             or cooperation&#xD;
&#xD;
          8. Taking any prescription or non-prescription medications at the time of the study&#xD;
&#xD;
          9. Having donated blood three months prior to and three months post study procedures&#xD;
&#xD;
         10. A pregnancy test will be performed 1 to 3 days prior to each study in all female&#xD;
             subjects. Those who test positive for pregnancy will be excluded.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Toronto General Hopital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>September 24, 2012</study_first_submitted>
  <study_first_submitted_qc>September 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2012</study_first_posted>
  <last_update_submitted>March 6, 2015</last_update_submitted>
  <last_update_submitted_qc>March 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intestinal lipoprotein</keyword>
  <keyword>Apo B48 and apoB100</keyword>
  <keyword>Pancreatic clamp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

